Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis [0.03%]
布罗利单抗治疗银屑病和银屑病关节炎的药物生存期和有效性的真实世界研究
Cathrine Dawn Büttner Elgaard,Lars Iversen,Kasper Fjellhaugen Hjuler
Cathrine Dawn Büttner Elgaard
Background: Clinical trials have established the efficacy of brodalumab in treatment of psoriasis and psoriatic arthritis. Real-world evidence is needed to fully evaluate the drug. ...
Estetrol: From Preclinical to Clinical Pharmacology and Advances in the Understanding of the Molecular Mechanism of Action [0.03%]
从非临床到临床药理学：关于分子作用机制的认识进展(estetrol)
Céline Gérard,Jean-Michel Foidart
Céline Gérard
Estetrol (E4) is the most recently described natural estrogen. It is produced by the human fetal liver during pregnancy and its physiological function remains unclear. E4 is the estrogenic component of a recently approved combined oral cont...
Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation [0.03%]
贝格尔酶β类似药治疗法布雷病的开发前临床评估
André B P van Kuilenburg,Carla E M Hollak,Ana Travella et al.
André B P van Kuilenburg et al.
Background and objective: Fabry disease (FD) is a rare lysosomal storage disorder caused by a deficiency of the enzyme α-galactosidase A (aGal A). Since 2001, two different enzyme replacement therapies have been authoriz...
Pharmacokinetics and Bioequivalence of Abiraterone Acetate Tablets in Healthy Chinese Volunteers: An Open, Randomized, Single-Dose, Three-Period, Three-Sequence Crossover Study [0.03%]
醋酸阿比特龙片在中国健康受试者中的药代动力学及生物等效性研究：一项开放、随机、单剂量、三周期、三序列交叉试验
Zhao-Xin Wu,Chen-Jing Wang,Ping Shi et al.
Zhao-Xin Wu et al.
Background and objective: Abiraterone acetate tablet is an inhibitor of androgen synthesis, primarily for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This study evaluated the bioequivalence a...
Randomized Controlled Trial
Drugs in R&D. 2023 Jun;23(2):121-127. DOI:10.1007/s40268-023-00418-6 2023
Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still's Disease [0.03%]
巴利昔맙治疗难治性成人斯蒂尔病患者的疗效
Ziyi Sun,Rongqi Li,Yingai Wang et al.
Ziyi Sun et al.
Background and objective: Adult-onset Still's disease (AOSD) is an idiopathic systemic inflammatory disease of unknown aetiology. Some patients exhibit resistance to conventional treatment during long-term therapy. Janus ...
Case Report: Simultaneously Induced Neutropenia and Hemolysis After a Single Metamizole Dose [0.03%]
病例报告：单次服用双氯芬酸后同时诱导的中性粒细胞减少和溶血
Raphael Allgaier,Arne Kandulski,Karsten Gülow et al.
Raphael Allgaier et al.
Background and objective: Metamizole is a non-opioid ampyrone sulfonate compound with potent analgesic, antipyretic, and spasmolytic effects. Agranulocytosis is a rare life-threatening complication of metamizole. ...
Case Reports
Drugs in R&D. 2023 Jun;23(2):93-98. DOI:10.1007/s40268-023-00415-9 2023
A Nontrivial Analysis of Patient Safety Risk from Parenteral Drug- and Medical Device-Borne Endotoxin [0.03%]
parenteral药品和医疗器械borne内毒素引起的患者安全风险的非平凡分析
Edward C Tidswell
Edward C Tidswell
Background: A thorough and systematic analysis of potential endotoxin-related safety issues from parenteral drugs and devices is important to ensure appropriate current Good Manufacturing Practices, compendial requirement...
Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr) [0.03%]
贝伐珠单抗类似药PF-06439535(Bevacizumab-bvzr)制剂开发
Rebecca L Ingram,Sarah E Weiser
Rebecca L Ingram
Background: PF-06439535 (bevacizumab-bvzr; Zirabev®) is a biosimilar of bevacizumab reference product (RP; Avastin®). This study describes the formulation development for PF-06439535. ...
Risk of Adverse Events Associated with Domperidone and Metoclopramide in Gastroparesis: Systematic Review and Meta-analysis [0.03%]
多潘立酮和甲氧氯普胺治疗胃轻瘫相关不良事件风险的系统评价和meta分析
Daniela R Junqueira,Dimitri Bennett,Susanna Y Huh et al.
Daniela R Junqueira et al.
Background: Dopamine antagonists are the main pharmacological options to treat gastroparesis. The aim of this study was to conduct a systematic literature review (SLR) to evaluate the profile of adverse events (AEs) of do...
Meta-Analysis
Drugs in R&D. 2023 Mar;23(1):1-20. DOI:10.1007/s40268-023-00413-x 2023
A Randomised Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Palovarotene Ophthalmic Solution [0.03%]
评估眼用溶液Palovarotene的安全性、耐受性和药代动力学的随机一期研究
William J Foster,Andrew L Strahs,Kent W Small et al.
William J Foster et al.
Background and objective: Palovarotene, a selective retinoic acid receptor γ agonist, is under investigation for the treatment of dry eye disease. This study aimed to determine the ocular and systemic safety, tolerabilit...
Clinical Trial
Drugs in R&D. 2023 Mar;23(1):43-53. DOI:10.1007/s40268-022-00410-6 2023